Mounzer Agha, MD

During a discussion at ASCO 2021, Mounzer Agha, MD, talked about mitigation strategies used by the investigators from the CARTITUDE-2 trial to prevent cognitive and neuro-movement disorders commonly associated with CAR T-cell therapy.

Agha emphasized that the annual conference allows investigators to set the foundation for what’s to come in the treatment of multiple myeloma and other hematologic malignancies.

Agha detailed updated findings from CARTITUDE-2 investigating cilta-cel for previously treated patients with multiple myeloma.